Assistant Professor, Pharmaceutical Sciences
Ph.D. (Pharmacology/Toxicology), University of Arizona, Tucson, AZ
M.S. (Toxicology), University of Arizona, Tucson, AZ
B.S. (Chemistry), University of Arizona, Tucson, AZ
Dr. Ham joined the faculty at Belmont University in the College of Pharmacy in 2012. Prior to joining the faculty, Dr. Ham was on faculty at Vanderbilt University School of Medicine (2003-2012) where she was initially a Research Assistant Professor of Biochemistry and an Associate Director of the Proteomics Laboratory in the Mass Spectrometry Research Center. More recently Dr. Ham was a Research Associate Professor of Biochemistry and senior faculty in the Jim Ayers Institute for Precancer Detection and Diagnosis in the Vanderbilt Ingram Cancer Center, where she maintains an adjunct appointment. Her research has primarily been collaborative in nature using proteomic and mass spectrometry approaches to study mechanisms of disease and for the discovery of biomarkers for detection, prognosis and treatment of various forms of cancers and other diseases. These collaborations have led to over 60 peer-reviewed publications. She has particular expertise in mass spectrometry, proteomic data analysis and analytical chemistry with focus on the analysis of protein post-translational modifications, protein-protein interactions, and complex proteomes. Her collaborators have ranged from cancer biologists and oncologists to experts in bioinformatics and analytical chemists.
Dr. Ham’s research interests include the use and further development of proteomics technologies and mass spectrometric approaches to enhance the discovery of protein biomarkers for personalized medicine. She has a particular interest in using these technologies to study various forms of breast cancer and to study how drugs and resistance to drugs change the proteome. She is also interested in the role that protein post-translational modifications play in the disease process and their use as biomarkers. Protein biomarkers could be used to better understand the mechanisms by which drugs may produce their therapeutic effect and to distinguish subsets of disease that may require a more personalized therapeutic approach. Specifically, these biomarkers would be used to a) track therapeutic effectiveness or resistance of drugs through the understanding of their mechanistic therapeutic effect and b) find new molecular targets for the development of drugs for both new targeted therapies and co-therapies. Dr. Ham also has an interest in protein-DNA crosslinks with respect to protein and/or gene specificity and the impact these modifications have on DNA repair and carcinogenesis.
View Dr. Ham's Curriculum Vitae
View Dr. Ham's Research Interests